X-Feed Billboard (International)

The newsboard processes news from the NASDAQ Nordic portfolio company GlobeNewswire, which provides investors with company-relevant information. This relates in particular to events that may be relevant to the listing of companies or tradable financial instruments.

GlobNewswire (formerly PrimeNewswire) specializes in public relations solutions and digital media services. This feed adds another important source of information for investors to the popular X-Billboard portfolio.

System-State: Number of processed items 38.688 Notifications successully processed since Inception
GlobeNewsWire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
CH0363463438
State: 26.11.2024 | 5AM
Do you already know our new terminal view? Click here.
FIGI: BBG00FXVZ9W8
IDIA

Idorsia Ltd
GICS: 35201010 · Sector: - · Sub-Sector: -
NAME
Idorsia Ltd
ISIN
CH0363463438
TICKER
IDIA
MIC
XSWX
REUTERS
IDIA.S
BLOOMBERG
IDIA SW
Mon, 11.11.2024       Idorsia

Allschwil, Switzerland – November 11, 2024

Tue, 29.10.2024       Idorsia

Ad hoc announcement pursuant to Art. 53 LR

Wed, 16.10.2024       Idorsia

Allschwil, Switzerland – October 16, 2024

Thu, 25.07.2024       Idorsia

Ad hoc announcement pursuant to Art. 53 LR

Thu, 18.07.2024       Idorsia

Idorsia will publish its Half Year 2024 Financial Reporting on Thursday July 25, 2024, at 07:00 CEST.

Mon, 01.07.2024       Idorsia

Allschwil, Switzerland – July 1, 2024
Idorsia Ltd (SIX: IDIA) announced today that the European Commission (EC) has approved JERAYGO (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.1 The recommended dose is 12.5 mg orally once daily. The dose can be increased to 25 mg once daily for patients tolerating the 12.5 mg dose and in need of tighter blood pressure (BP) control.1

Fri, 28.06.2024       Idorsia

Allschwil, Switzerland – June 28, 2024

Tue, 25.06.2024       Idorsia

Ad hoc announcement pursuant to Art. 53 LR

Fri, 21.06.2024       Idorsia

Allschwil, Switzerland – June 21, 2024
Idorsia Ltd (SIX: IDIA) announced today that its novel treatment for chronic insomnia has been awarded the prestigious Prix Galien Suisse 2024 innovation prize in the ‘Primary & Speciality’ category. The Prix Galien Suisse is awarded annually to the most innovative new medicines and diagnostics on the Swiss market, as judged by a jury of renowned Swiss scientists.

Thu, 13.06.2024       Idorsia

Allschwil, Switzerland – June 13, 2024
At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board of Directors with very large majorities.

Mon, 03.06.2024       Idorsia

Allschwil, Switzerland – June 3, 2024

Fri, 31.05.2024       Idorsia

Allschwil, Switzerland – May 31, 2024

Thu, 23.05.2024       Idorsia

Allschwil, Switzerland – May 23, 2024

Tue, 21.05.2024       Idorsia

Ad hoc announcement pursuant to Art. 53 LR

Tue, 21.05.2024       Idorsia

Ad hoc announcement pursuant to Art. 53 LR

Tue, 21.05.2024       Idorsia

Ad hoc announcement pursuant to Art. 53 LR

Mon, 06.05.2024       Idorsia

Ad hoc announcement pursuant to Art. 53 LR

Wed, 01.05.2024       Idorsia

Ad hoc announcement pursuant to Art. 53 LR

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.


On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.